Target intelligence / Profile preview

Ribosomal L24 domain containing 1 pseudogene 4 (RSL24D1P4)

Target: RSL24D1P4
Molecular classification: Other (Pseudogene; processed pseudogene of ribosomal protein L24 family)

Overview

Ribosomal L24 domain containing 1 pseudogene 4 (RSL24D1P4) is a processed pseudogene that belongs to the family of ribosomal protein L24-related sequences. While RSL24D1P4 does not encode a functional protein, similar pseudogenes have been implicated in gene regulation through competing endogenous RNA mechanisms or microRNA sponge activity[6]. There are no known therapeutic uses, disease roles, drug interactions, or biomarker applications specific to RSL24D1P4. However, related ribosomal pseudogenes (such as RPL4P4, not RSL24D1P4) have shown altered expression in certain cancers and may act as biomarkers or regulatory RNAs in those contexts[2]. RSL24D1P4 should not be considered a biological target for drug development. RSL24D1 (Ribosomal L24 domain containing 1) is a protein-coding gene involved in ribosome biogenesis[7]. RSL24D1P4 is a pseudogene derived from this locus, lacking protein-coding function, and is not a therapeutic target[1][7]. If the intent was to query RSL24D1, a biologically active protein, please respecify.

Other names: RSL24D1P19

Mechanism of action

None. There are no drugs targeting RSL24D1P4 or known mechanisms of action for this pseudogene[1].

Biological functions

No canonical protein-coding function. Potential regulatory roles in gene expression by acting as endogenous RNA competitors or microRNA sponges, a function assigned to some pseudogenes[6].

Disease associations

No direct evidence for RSL24D1P4, but research on similar ribosomal pseudogenes (e.g., RPL4P4) suggests links to cancer, including glioma progression and prognosis when highly expressed[2]. However, this evidence does not specifically pertain to RSL24D1P4.

Safety considerations

None known. No therapies target RSL24D1P4, thus no safety issues are associated[1][6].

Interacting drugs

None reported. No known small molecules or drugs interact with RSL24D1P4 or target pseudogenes directly[1][6].

Biomarkers

None specifically for RSL24D1P4. However, by analogy with other pseudogenes, elevated expression in tumors may serve as a biomarker for prognosis or subtype—this has been observed for RPL4P4, not RSL24D1P4[2].

Beyond the preview

Go deeper on Ribosomal L24 domain containing 1 pseudogene 4 (RSL24D1P4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal L24 domain containing 1 pseudogene 4 (RSL24D1P4).

Explore the full profile